Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event
Main finding · Major fracture rateResult — go to the resultIncidence rate ratio 2.43 95% CI 1.34–4.27Authors' conclusion
Fracture risk may be increased in cancer patients early after initiation of ICI, and this may represent a novel immune-related adverse event.
Study context
- Population
- All individuals treated with immune checkpoint inhibitor (ICI) for cancer, Alberta Cancer Registry, September 29, 2010 to March 31, 2019 (mean age 65.7 years, 60% male)
- Participants
- 1,600 ICI users
- Exposure
- Fracture rate in the year after vs the year prior to ICI initiation
- Outcome
- Fracture rate (fracture diagnostic codes) after ICI initiation compared to baseline
- Follow-up
- Up to two years after ICI initiation
Methodological detailspopulation-based, self-controlled comparison of fracture rates before vs after ICI initiation, linked healthcare administrative databases
- Population-based
- Self-controlled comparison of fracture rates before vs after ICI initiation
- Linked healthcare administrative databases
Main finding
Major fracture rate
Incidence rate ratio
2.43
95% CI 1.34–4.27
By group
Year 1 after ICIvs Year prior to ICI
IRR 2.43 (95% CI 1.34–4.27)
As reported in the abstract
Observational data: associations, not effects.
Original publication
Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event. Osteoporos Int. Published 2 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →